These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16773073)

  • 1. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases.
    Stea B; Shaw E; Pintér T; Hackman J; Craig M; May J; Steffen RP; Suh JH
    Br J Cancer; 2006 Jun; 94(12):1777-84. PubMed ID: 16773073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
    Suh JH; Stea B; Nabid A; Kresl JJ; Fortin A; Mercier JP; Senzer N; Chang EL; Boyd AP; Cagnoni PJ; Shaw E
    J Clin Oncol; 2006 Jan; 24(1):106-14. PubMed ID: 16314619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases.
    Scott C; Suh J; Stea B; Nabid A; Hackman J
    Am J Clin Oncol; 2007 Dec; 30(6):580-7. PubMed ID: 18091051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of efaproxiral in metastatic brain tumors.
    Engel RH; Kaklamani VG
    Expert Rev Anticancer Ther; 2006 Apr; 6(4):477-85. PubMed ID: 16613536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efaproxiral: a novel radiation sensitiser.
    Suh JH
    Expert Opin Investig Drugs; 2004 May; 13(5):543-50. PubMed ID: 15155129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efaproxiral: a radiation enhancer used in brain metastases from breast cancer.
    Charpentier MM
    Ann Pharmacother; 2005 Dec; 39(12):2038-45. PubMed ID: 16249270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.
    Kavanagh BD; Khandelwal SR; Schmidt-Ullrich RK; Roberts JD; Shaw EG; Pearlman AD; Venitz J; Dusenbery KE; Abraham DJ; Gerber MJ
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1133-9. PubMed ID: 11240256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
    Choy H; Nabid A; Stea B; Scott C; Roa W; Kleinberg L; Ayoub J; Smith C; Souhami L; Hamburg S; Spanos W; Kreisman H; Boyd AP; Cagnoni PJ; Curran WJ
    J Clin Oncol; 2005 Sep; 23(25):5918-28. PubMed ID: 16135463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.
    Kleinberg L; Grossman SA; Carson K; Lesser G; O'Neill A; Pearlman J; Phillips P; Herman T; Gerber M
    J Clin Oncol; 2002 Jul; 20(14):3149-55. PubMed ID: 12118029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.
    Shaw E; Scott C; Suh J; Kadish S; Stea B; Hackman J; Pearlman A; Murray K; Gaspar L; Mehta M; Curran W; Gerber M
    J Clin Oncol; 2003 Jun; 21(12):2364-71. PubMed ID: 12805339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival.
    Stea B; Suh JH; Boyd AP; Cagnoni PJ; Shaw E;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1023-30. PubMed ID: 16446056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme.
    Kleinberg L; Grossman SA; Piantadosi S; Pearlman J; Engelhard H; Lesser G; Ruffer J; Gerber M
    J Clin Oncol; 1999 Aug; 17(8):2593-603. PubMed ID: 10561327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice.
    Hou H; Khan N; Grinberg OY; Yu H; Grinberg SA; Lu S; Demidenko E; Steffen RP; Swartz HM
    Radiat Res; 2007 Aug; 168(2):218-25. PubMed ID: 17638413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of efaproxiral (RSR13) and its metabolites in equine by liquid chromatography tandem mass spectrometry.
    Yi R; Sandhu J; Zhao S; Lam G; Loganathan D; Morrissey B
    J Mass Spectrom; 2014 Jan; 49(1):57-67. PubMed ID: 24446264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study.
    Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Demidenko E; Lu S; Steffen RP; Swartz HM
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1503-9. PubMed ID: 15817356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice.
    Khandelwal SR; Kavanagh BD; Lin PS; Truong QT; Lu J; Abraham DJ; Schmidt-Ullrich RK
    Br J Cancer; 1999 Feb; 79(5-6):814-20. PubMed ID: 10070874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric modification of hemoglobin by RSR13 as a therapeutic strategy.
    Steffen RP; Liard JF; Gerber MJ; Hoffman SJ
    Adv Exp Med Biol; 2003; 530():249-59. PubMed ID: 14562722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efaproxiral (RSR13) plus oxygen breathing increases the therapeutic ratio of carboplatin in EMT6 mouse mammary tumors.
    Donnelly ET; Liu Y; Rockwell S
    Exp Biol Med (Maywood); 2006 Mar; 231(3):317-21. PubMed ID: 16514179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.
    Mehta MP; Wang D; Wang F; Kleinberg L; Brade A; Robins HI; Turaka A; Leahy T; Medina D; Xiong H; Mostafa NM; Dunbar M; Zhu M; Qian J; Holen K; Giranda V; Curran WJ
    J Neurooncol; 2015 Apr; 122(2):409-17. PubMed ID: 25682091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.